Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate

Robert T. Dess, Krithika Suresh, Michael J. Zelefsky, Stephen J. Freedland, Brandon A. Mahal, Matthew R. Cooperberg, Brian J. Davis, Eric M. Horwitz, Martha K. Terris, Christopher L. Amling, William J. Aronson, Christopher J. Kane, William C. Jackson, Jason W.D. Hearn, Curtiland Deville, Theodore L. Deweese, Stephen Greco, Todd R. McNutt, Daniel Y. Song, Yilun SunRohit Mehra, Samuel D. Kaffenberger, Todd M. Morgan, Paul L. Nguyen, Felix Y. Feng, Vidit Sharma, Phuoc T. Tran, Bradley J. Stish, Thomas M. Pisansky, Nicholas G. Zaorsky, Fabio Ynoe Moraes, Alejandro Berlin, Antonio Finelli, Nicola Fossati, Giorgio Gandaglia, Alberto Briganti, Peter R. Carroll, R. Jeffrey Karnes, Michael W. Kattan, Matthew J. Schipper, Daniel E. Spratt

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Importance: In 2016, the American Joint Committee on Cancer (AJCC) established criteria to evaluate prediction models for staging. No localized prostate cancer models were endorsed by the Precision Medicine Core committee, and 8th edition staging was based on expert consensus. Objective: To develop and validate a pretreatment clinical prognostic stage group system for nonmetastatic prostate cancer. Design, Setting, and Participants: This multinational cohort study included 7 centers from the United States, Canada, and Europe, the Shared Equal Access Regional Cancer Hospital (SEARCH) Veterans Affairs Medical Centers collaborative (5 centers), and the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry (43 centers) (the STAR-CAP cohort). Patients with cT1-4N0-1M0 prostate adenocarcinoma treated from January 1, 1992, to December 31, 2013 (follow-up completed December 31, 2017). The STAR-CAP cohort was randomly divided into training and validation data sets; statisticians were blinded to the validation data until the model was locked. A Surveillance, Epidemiology, and End Results (SEER) cohort was used as a second validation set. Analysis was performed from January 1, 2018, to November 30, 2019. Exposures: Curative intent radical prostatectomy (RP) or radiotherapy with or without androgen deprivation therapy. Main Outcomes and Measures: Prostate cancer-specific mortality (PCSM). Based on a competing-risk regression model, a points-based Score staging system was developed. Model discrimination (C index), calibration, and overall performance were assessed in the validation cohorts. Results: Of 19684 patients included in the analysis (median age, 64.0 [interquartile range (IQR), 59.0-70.0] years), 12421 were treated with RP and 7263 with radiotherapy. Median follow-up was 71.8 (IQR, 34.3-124.3) months; 4078 (20.7%) were followed up for at least 10 years. Age, T category, N category, Gleason grade, pretreatment serum prostate-specific antigen level, and the percentage of positive core biopsy results among biopsies performed were included as variables. In the validation set, predicted 10-year PCSM for the 9 Score groups ranged from 0.3% to 40.0%. The 10-year C index (0.796; 95% CI, 0.760-0.828) exceeded that of the AJCC 8th edition (0.757; 95% CI, 0.719-0.792), which was improved across age, race, and treatment modality and within the SEER validation cohort. The Score system performed similarly to individualized random survival forest and interaction models and outperformed National Comprehensive Cancer Network (NCCN) and Cancer of the Prostate Risk Assessment (CAPRA) risk grouping 3-and 4-tier classification systems (10-year C index for NCCN 3-tier, 0.729; for NCCN 4-tier, 0.746; for Score, 0.794) as well as CAPRA (10-year C index for CAPRA, 0.760; for Score, 0.782). Conclusions and Relevance: Using a large, diverse international cohort treated with standard curative treatment options, a proposed AJCC-compliant clinical prognostic stage group system for prostate cancer has been developed. This system may allow consistency of reporting and interpretation of results and clinical trial design.

Original languageEnglish (US)
Pages (from-to)1912-1920
Number of pages9
JournalJAMA Oncology
Issue number12
StatePublished - Dec 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate'. Together they form a unique fingerprint.

Cite this